Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review
- 05.06.2024
- General Review
Erschienen in:
- Verfasst von
- Shinji Tsukamoto
- Andreas F. Mavrogenis
- Tomoya Masunaga
- Hisaki Aiba
- Ayano Aso
- Kanya Honoki
- Hiromasa Fujii
- Akira Kido
- Yuu Tanaka
- Yasuhito Tanaka
- Costantino Errani
- Erschienen in
- European Journal of Orthopaedic Surgery & Traumatology | Ausgabe 6/2024
Abstract
Purpose
Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with cancer, such as melanoma, renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), and urothelial carcinoma. The extension of life expectancy has led to an increased incidence of bone metastases (BM) among patients with cancer. BM result in skeletal-related events, including severe pain, pathological fractures, and nerve palsy. Surgery is typically required for the treatment of BM in patients with an impending fracture; however, it may be avoided in those who respond to ICIs. We systematically reviewed studies analyzing BM responses to treatment with ICIs.
Methods
This study was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 statement and registered in the UMIN Clinical Trials Registry (ID: UMIN000053707). Studies reporting response rates based on the Response Evaluation Criteria in Solid Tumors (RECIST) or the MD Anderson Cancer Center (MDA) criteria specific for BM in patients treated with ICIs were included; reports of fewer than five cases and review articles were excluded. Studies involving humans, published in English and Japanese, were searched. The PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched. Ultimately, nine studies were analyzed. The Risk of Bias Assessment tool for Non-randomized Studies was used to assess the quality of studies.
Results
Based on the MDA criteria, complete response (CR) or partial response (PR) was observed in 44–78% and 62% patients treated with ICIs plus denosumab for NSCLC and melanoma, respectively. According to the RECIST, CR or PR was recorded in 5% and 7–28% of patients treated with ICIs for renal cell carcinoma and urothelial carcinoma, respectively.
Conclusion
Although response rates to ICIs for BM are poor, patients treated with ICI plus denosumab for bone metastases with impending fractures from NSCLC and melanoma are likely to avoid surgery to prevent fractures.
Anzeige
- Titel
- Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review
- Verfasst von
-
Shinji Tsukamoto
Andreas F. Mavrogenis
Tomoya Masunaga
Hisaki Aiba
Ayano Aso
Kanya Honoki
Hiromasa Fujii
Akira Kido
Yuu Tanaka
Yasuhito Tanaka
Costantino Errani
- Publikationsdatum
- 05.06.2024
- Verlag
- Springer Paris
- Erschienen in
-
European Journal of Orthopaedic Surgery & Traumatology / Ausgabe 6/2024
Print ISSN: 1633-8065
Elektronische ISSN: 1432-1068 - DOI
- https://doi.org/10.1007/s00590-024-04018-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
